最佳全身治疗对比联合原发灶局部治疗在转移性前列腺癌的2期随机对照试验
这项多中心2期随机试验纳入119例初诊转移性前列腺癌患者,在6个月最佳全身治疗后随机分为继续全身治疗或联合原发灶局部治疗(放疗或手术)。主要终点无进展生存期在两组间无显著差异(中位17.9个月 vs 14.8个月,HR 0.89,95%CI 0.59-1.34,p=0.6)。总生存期影响正在3期试验中验证。
要点
- 局部治疗未改善初诊转移性前列腺癌的无进展生存期。
- 联合局部治疗组3级毒性发生率为6.7%,对照组为0%。
- AVPC分子特征与更差的无进展生存期显著相关(HR 1.74,p=0.04)。
核心结论
- 在初诊转移性前列腺癌患者中,最佳全身治疗联合原发灶局部治疗未能改善无进展生存期。
研究设计与样本
- 多中心、随机、2期试验,2013年3月至2018年4月纳入119例初诊M1前列腺癌患者,按1:1随机分为最佳全身治疗组(59例)和最佳全身治疗联合局部治疗组(60例)。
主要发现
- 中位无进展生存期在最佳全身治疗组为17.9个月(95%CI 11.7-36.4),联合局部治疗组为14.8个月(95%CI 11.4-42.9),HR 0.89(95%CI 0.59-1.34,p=0.6)。
- 联合局部治疗组4例(6.7%)发生3级毒性,最佳全身治疗组0例。
- 最佳全身治疗组3例因症状性局部进展需姑息干预,另有6例在达到去势抵抗性前列腺癌进展标准后交叉接受局部治疗。
- CHAARTED高瘤负荷(HR 1.84,95%CI 1.06-3.19)和临床cT3b/T4疾病(HR 1.97,95%CI 0.88-4.41)与更差的总生存期相关。
- 基线或6个月时AVPC分子特征与更差的无进展生存期显著相关(HR 1.74,95%CI 1.02-2.98,p=0.04),但与总生存期无统计学显著关联(HR 1.83,95%CI 0.94-3.56,p=0.08)。
临床怎么用
- 对于初诊转移性前列腺癌,在最佳全身治疗基础上联合原发灶局部治疗未显示无进展生存期获益,总生存期影响待3期试验(SWOG 1802)结果。
- CHAARTED瘤负荷、cT3b/cT4疾病和AVPC-MS可能作为预后生物标志物,但需进一步评估以优化治疗选择和分层。
局限性
- 本文为2期试验,样本量有限,总生存期数据尚未成熟,局部治疗对总生存期的影响需等待正在进行的3期试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Studies reported to date indicate that local therapy may improve outcomes in men with de novo metastatic (M1) prostate cancer (PCa). The aim of this study was to evaluate the effect of local therapy to the primary tumor on progression-free survival (PFS) in men with M1 PCa. METHODS: In a multicenter, randomized phase 2 trial, men with de novo M1 PCa, after receiving 6 mo of best systemic therapy (BST), were randomly assigned (1:1) to continue BST alone (arm 1) or BST with the addition of either radiotherapy or surgery to their primary tumor (arm 2). The primary endpoint was PFS, defined as the time from randomization to progression (Prostate Cancer Working Group 2) by prostate-specific antigen, radiographic or symptomatic progression, or the time to change systemic therapy as per physician discretion and/or clinical decision, or death, whichever occurred first. Immunohistochemistry for the tumor suppressors p53, RB1, and PTEN was performed on available prostate biopsies at baseline and 6 mo. The aggressive variant PCa molecular signature (AVPC-MS) was assigned if two or more of these tumor suppressors were abnormal. In the current intent-to-treat analysis, the Kaplan-Meier product-limit method was used to estimate the median PFS. KEY FINDINGS AND LIMITATIONS: Between March 2013 and April 2018, 119 patients were randomized (arm 1: 59 and arm 2: 60). The median follow-up for patients who survived was 66 mo (64 mo for BST alone and 67 mo for BST plus local therapy groups). BST included androgen deprivation therapy (n = 119), with docetaxel (n = 37) or with androgen receptor pathway inhibitor agents (n = 9). Local therapy included surgery (n = 45), radiation (n = 13), or none (n = 2). At data analysis, 88 patients met Prostate Cancer Working Group 2 progression, and 53 patients had died. The median PFS was 17.9 mo (95% confidence interval [CI] 11.7-36.4) in arm 1 and 14.8 mo (95% CI 11.4-42.9) in arm 2 (hazard ratio [HR] 0.89, 95% CI 0.59-1.34, p = 0.6). Toxicity was limited in both arms, with grade 3 toxicities in four patients (6.7%) in arm 2 and zero patients in arm 1. Three patients required palliative intervention for symptomatic local progression in arm 1, while an additional six patients crossed over to receive local therapy after meeting castration-resistant PCa progression criteria. Predictors of worse overall survival (OS) for all comers included CHAARTED high-volume (HR 1.84, 95% CI 1.06-3.19) and clinical cT3b/T4 (HR 1.97, 95% CI 0.88-4.41) disease. Having the AVPC molecular profile (AVPC-MS) at baseline or 6 mo was significantly associated with worse PFS (HR 1.74, 95% CI 1.02-2.98, p = 0.04). However, there was no statistically significant association with OS (HR 1.83, 95% CI 0.94-3.56, p = 0.08). CONCLUSIONS AND CLINICAL IMPLICATIONS: This phase 2 randomized study failed to demonstrate improved PFS in men with de novo M1 PCa treated with BST with the addition of local therapy to their primary tumor. Its effect on OS is being tested in an ongoing phase 3 trial (SWOG 1802). We identified biomarkers of potential prognostic value (CHAARTED volume status, cT3b/cT4 disease, and the AVPC-MS) that may serve to optimize therapy selection and stratification in this population, but these require further evaluation.
引用
- Chapin BF, Smaldone M, Zurita AJ, et al. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Eur Urol. 2026. PMID: 41833492. doi:10.1016/j.eururo.2026.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。